Home

Welcome

Haemostatix has developed a new class of active clotting agent, or "haemostat" for the control of bleeding. The company has pioneered a new approach to haemostasis that is based on a peptide that binds to the protein fibrinogen, inducing the rapid and targeted formation of clots. This innovative technology platform is being used to develop a pipeline of topical and systemic products to treat different forms of bleeding.

Haemostatix's pipeline includes:

PeproStat™, a topical haemostat that is applied directly to wounds to rapidly control bleeding during surgery. PeproStat has a novel mode of action that is fast and effective. It is manufactured from blood-free components and will be available in a range of ready-to-use formulations. Current products are typically blood-derived and often require preparation prior to use. PeproStat is scheduled to enter clinical trials during 2013, subject to regulatory approval.

HaemoPlax™, is a platelet substitute in development for the prevention of bleeding in leukaemic patients with platelet deficiency (thrombocytopenia).

HXTC901 is a 'pro-drug' version of HaemoPlax that is activated by the enzyme thrombin at a wound site. HXTC 901 is designed to control more active bleeds in surgery or trauma.

Haemostatix is based at BioCity, Nottingham, UK in the City's Creative Quarter More...

News

31st October 2012 - Wellcome Trust and investors back clinical development of new haemostat to control surgical bleeding - Haemostatix Ltd, a biopharmaceutical company, announced today that it has received an additional £1.4 million Translation Award from the Wellcome Trust to continue development of its innovative haemostat technology. The funding coincides with a further £800,000 investment from Albion Ventures, Catapult Venture Managers, Spark Ventures, Esperante, Nesta, the Lachesis Fund, The University of Leicester and private share-holders. The new funds will enable Haemostatix to progress its lead product, PeproStat, into clinical trials.

13th June 2011 - Haemostatix Ltd, a biopharmaceutical company, announced that it has received an investment from Esperante to support development of its innovative haemostat technology. This is the third round of funding the Company has secured in the last 12 months.

5th November 2010 - Wellcome Trust and investors back development of new surgical haemostat. Haemostatix Ltd, a biopharmaceutical company, announced today that it has received a £409,000 Translation Award from the Wellcome Trust to support development of its innovative haemostat technology. The funding coincides with an additional £459,000 investment from Spark Ventures, Catapult Venture Managers, NESTA, the Lachesis Fund and Leicester University as well as new investor, Nottingham’s Mobius Technology Ventures.